Global Respiratory Infectious Disease Diagnostics Market - 2020-2027
発行: DataM Intelligence
Respiratory infections are caused by virus, bacteria, and other microbes, which further infect the respiratory system including the lungs, throat, and airways. Spread of infections is often through mucus and saliva that is usually expelled when the person sneezes, coughs, or laughs. Few of the germs are also spread though droplets that spread through air and also spread through travelling, which causes respiratory infections. Furthermore, some people can be infected by touching the remaining microbes on the surface, or touching contaminated hands.
Rising levels of hazardous gases and pollutants will lead to various lung disorders such as respiratory diseases including bronchitis, asthma, COPD, and Emphysema, among others. Further, a growing population base in developed and underdeveloped countries and the rising inclination towards a sedentary lifestyle may contribute to the market growth. COVID-19 outbreak has affected patients with severe respiratory distress, thereby increasing the demand for respiratory disease testing market.
Various conditions affect different parts of respiratory system and hinder the ability to breathe. These conditions can be chronic or infectious. Chronic lung diseases fall into one of two main classes, obstructive or restrictive. People with weakened lungs and immune systems are more vulnerable to infectious respiratory conditions. Some individuals have multiple lung conditions.
The market is driven is the rising burden of respiratory diseases and technological advancements in the products. Chronic Obstructive Pulmonary Disease is a progressive lung disorder which causes reduction in airflow. According to the World Health Organization, 90% of the COPD deaths occur in low- and middle-income countries. Approximately 251 million cases of COPD were reported globally as per the study of the Global Burden of Disease Study. It is expected to increase in the coming years due to increasing aging population and changing lifestyle of people. Therefore, early diagnosis and treatment is very important which is expected to boost the market growth.
Recent pandemic resulting into widespread COVID 19 infections across the globe is a major factor that is estimated to boost the demand for diagnosis during forecast period. As per current statistics, in April 2020, 6.08 million people across globe were infected with COVID 19 diseases, and this is likely to impact the need for rapid diagnostics testing. This factor is likely to boost the respiratory infectious diagnostics market during forecast period.
According to data published in January 2020, 2519 laboratory-conformed cases of Middle East respiratory syndrome (MERS), were reported, which includes 866 associated deaths globally. Majority of cases reported were from Saudi Arabia (2121 cases), including 788 related deaths with a higher fatality rate of 37.1%. Moreover, the emergence of COVID-19 pandemic has driven the demand for faster diagnosis. According to statistics, in May 2020, there were around 6.08 million COVID-19 cases reported globally, which boosts the need for early diagnosis of diseases. This factor will drive the growth of market in the forecast period.
Rapid rise in burden of chronic obstructive pulmonary disorders such as chronic bronchitis, emphysema, asthma, and other lung diseases such as tuberculosis, pneumonia, is estimated to boost the respiratory infectious disease diagnostics market. Furthermore, rising lower respiratory infectious disease drives the need for early detection, which further drivers the demand for diagnostics tests. This factor will drive the growth of market in the forecast period.
However, stringent regulatory framework coupled with unfavorable reimbursement policies and low awareness rate among the patient population will hamper the growth of the market in the forecast period.
The global respiratory infectious disease diagnostics market is segmented based on disease type by coronavirus infections, Middle East Respiratory Syndrome (MERS), tuberculosis, others . The coronavirus infections segment held the largest market share. According to the WHO, SARS-CoV-2 has spread to over 150 countries with over 460,000 confirmed cases and over 20,000 deaths as of 27th March 2020. According to an article published in the World Economic Forum in March 2020, among the 500 people being hospitalized in the U.S., 20% were aged between 20 to 44 years and 18 % were aged between 45-54 years. This factor would drive the growth of the market in the forecast period.
People with existing illnesses such as cardiovascular disease, chronic respiratory disease, hypertension, and diabetes are expected to experience a higher than average fatality rate. Moreover, according to the Chinese CDC, males are more vulnerable to becoming severely ill with the virus than women. The male fatality rate is 2.8% and the female fatality rate is 1.7%. This factor will drive the growth of market in the forecast period.
The tuberculosis segment is expected to have positive market growth in the forecast period. Tuberculosis is a bacterial infection that affects the lungs and other parts of the body. TB can be inactive, or latent, for many years. The landscape of TB diagnostics has changed dramatically during the past ten years. Moreover, in response to WHO's Global TB Program, it has implemented a systematic and dynamic process, that is used to evaluate technologies and develop policies.
The high-risk countries are undertaking national efforts to reduce disease burden. For instance, the Chinese government obtained financial aid through a partnership with the Bill & Melinda Gates Foundation to enhance detection and treatment of TB. The foundation supported the initiative through a grant of USD 33 million for five years from 2009-2014. This factor will drive the growth of the market in the forecast period.
Further, the market is also classified based on test type as imaging tests, mechanical tests, in-vitro diagnostic tests and others. The imaging tests segment is held the largest market share. The prime reason for the dominance of the segment is increased adoption of x-ray imaging and other imaging modalities for better visualization and a clear picture of disease condition.
An imaging test is a way to let doctors see what's going on inside patient's body. These tests send forms of energy (like x-rays, sound waves, radioactive particles, or magnetic fields) through the body. The body tissues change the energy patterns to make an image or picture. These pictures show how patient's insides look and work so that health care providers can see changes that may be caused by diseases like lungs cancer.
Many health care providers plan x-rays or other imaging tests before treatment starts. These pictures are then used to track changes during treatment. These are called baseline studies because they show how things looked at the start. They can be compared with later images to see the results of treatment over time. This factor will drive the growth of market in the forecast period.
In-vitro diagnostics tests has positive growth in the Respiratory Disease Testing market. The major contributing factor for the market growth is the shift from traditional diagnostics to a new generation diagnostics that work at the gene level. This was made possible by the inclusion of advanced technologies, such as genetic testing, molecular diagnostics, and polymerase chain reaction (PCR) and next-generation sequencing (NGS). Recently (2020), Qiagen received a CE mark in the Europe for QIAstat-Dx test kit for the detetction of SARS-CoV-2 coronavirus.
By region, the global respiratory infectious disease diagnostics market is segmented into North America, South America, Europe, Asia-Pacific, Middle-East, and Africa. Among all of the regions, North America dominated the global respiratory infectious disease diagnostics market and is expected to grow at the highest CAGR during the forecast period due to growing burden of respiratory diseases and higher prevalence of smoking.
According to the Centre for Disease Control and Prevention, in 2018, the prevalence of Asthma was found to be around 6.2% in male and 9.1% in female in the United States. Furthermore, around 6.2% of people were reported with chronic obstructive pulmonary diseases in the United States. Hence, these factors are expected to drive the growth of market in the forecast period.
Adoption of rapid diagnostics tests for faster diagnosis of respiratory infectious diseases is another key factor that is anticipated to augment the respiratory infectious disease diagnostics market in the region. As per CDC statistics, in May 2020, the Real-Time Reverse Transcriptase (RT)-PCR Diagnostic Panel is efficient in detecting the SARS-CoV-2 virus in respiratory specimens. The USFDA also offered its Emergency Use Authorization (EUA) for this test in February 2020. These factors are expected to drive the growth of market in the forecast period.
The Europe was the second-largest market followed by Asia Pacific, owing to the rising prevalence of COPD disease in the region. For instance, according to the European Respiratory Nurses Association (ERNA), 259,000 people die of COPD each year in the EU. Moreover, rising cases of COVID 19 in Italy, Spain, the U.K. and other countries across Europe is boosting the need for diagnosis of respiratory infectious diseases across the region.
In Feb 2020, with respect to rising COVID diseases, the molecular diagnostics tests, serology tests, and antigen tests have been approved for faster diagnosis of the COVID 19 disease. Hence, these factors are expected to drive the growth of market in the region.
The global respiratory infectious disease diagnostics market is highly competitive with the presence of several international and local markets. Product diversification, revenue generation, and opportunities intensify the market competition Abbott Laboratories, Thermo Fisher Scientific Inc., Alere, Inc., Koninklijke Philips N.V., Cardinal Health, COSMED, Smiths Group plc, NIHON KOHDEN CORPORATION, Becton, Dickinson and Company, and F. Hoffmann-La Roche AG. are the leading market players with significant market share. The major players are using product development, novel product launches, market expansion, and product diversification strategies for holding their position in the market.
The companies are entering into collaborations, mergers, strategic partnerships, and acquisitions to expand their presence and meet the rising demand for the respiratory infectious disease diagnostics across the globe. For instance, in August 2020, Novacyt an international specialist in clinical diagnostics, announces the launch of its CE-Mark approved polymerase chain reaction (PCR) respiratory test panel, Winterplex™. The test panel is designed to be used on any open PCR platform, including the Company's rapid, portable q32 instrument.